Spatial Metabolomics Technology Landscape — PatSnap Eureka
Spatial Metabolomics: Imaging Mass Spectrometry, Multi-Omics Integration & Deep Learning
Spatial metabolomics maps metabolites, lipids, and small molecules directly within tissue sections at 10–100 µm resolution, preserving spatial context lost in conventional bulk analysis. This landscape covers IMS annotation engines, spatial multi-omics co-registration patents, and the deep learning frontier from 2008 to 2025.
Imaging Mass Spectrometry at the Core of Spatial Metabolomics
Spatial metabolomics relies on imaging mass spectrometry (IMS) — primarily matrix-assisted laser desorption/ionization (MALDI) and related ionization methods — to acquire mass spectra at spatially resolved pixel positions across a tissue section. Each pixel generates an ion image revealing the anatomical distribution of individual metabolites at a spatial resolution typically ranging from 10 µm to 100 µm per pixel, depending on instrument configuration. This spatial fidelity is what distinguishes the discipline from conventional bulk metabolomics, which destroys tissue architecture in the extraction process.
The dominant analytical platform in the retrieved records is IMS combined with cloud-based annotation engines. The METASPACE platform exemplifies this approach: a community-populated knowledge base that ingests IMS datasets from labs worldwide and returns confidence-controlled metabolite annotations via a high-performance computational engine. As of its 2019 publication, METASPACE already hosted over 3,000 datasets spanning human cancer cohorts, whole-body animal sections, and organ-level tissue maps. For analytical context, see the PatSnap Analytics platform for patent landscape tools.
A secondary but rapidly growing sub-domain involves the spatial integration of metabolomics with other omics layers — specifically spatial transcriptomics. Patents filed by Shanghai Luming Biotech and Zhejiang University describe algorithmic frameworks for registering and co-aligning spatial metabolomics imaging coordinates with spatial transcriptomics spot grids, enabling point-to-point data fusion across fundamentally different coordinate systems and detection resolutions. The European Bioinformatics Institute (EMBL-EBI) has been a central contributor to community IMS infrastructure.
From Foundational Infrastructure to Deep Learning Fusion: 2008–2025
Publication dates across retrieved results reveal a clear acceleration in spatial-specific work from 2019 onward, culminating in deep learning–based multi-omics integration patents in 2023–2025.
Innovation Milestones by Era
Key platform and patent events mapped across four developmental phases from pre-2015 foundations to the 2023–2025 deep learning frontier.
METASPACE Dataset Growth & ML Training Scale
METASPACE grew from community experiments to a 3,000+ dataset knowledge base by 2019; METASPACE-ML (2023) trained on a curated 1,710-dataset corpus from 47 labs.
Four Innovation Clusters Shaping the Spatial Metabolomics Landscape
The retrieved patent and literature records cluster into four distinct technical approaches, from cloud-based annotation to deep learning–driven multi-omics fusion.
Cloud-Based IMS Annotation Engines
METASPACE operates by matching detected ion images against metabolite databases in a confidence-controlled manner using false discovery rate (FDR) estimation to ensure cross-experiment comparability. The 2023 upgrade, METASPACE-ML, replaces rule-based scoring with a machine learning model trained on 1,710 heterogeneous datasets from 47 laboratories, achieving higher precision and better recovery of low-intensity, biologically relevant metabolites. The platform draws on natural language processing–inspired methods to extend molecular coverage beyond any single database.
3,000+ datasets hosted by 2019Spatial Multi-Omics Co-Registration & Integration
Patents from Shanghai Luming Biotech (2023, 2025) and Zhejiang University (2025) address the algorithmic challenge of fusing spatial metabolomics data with spatial transcriptomics. Spatial transcriptomics chips use 55 µm diameter spots on a 6.5 mm × 6.5 mm array, while IMS operates on pixel grids at 100 µm × 100 µm resolution across areas up to 10 cm × 10 cm. These patents propose coordinate transformation pipelines using fiducial landmarks from HE-stained tissue images to achieve spot-to-pixel alignment. The SpatialData framework (2023) establishes a universal file format for multi-modal spatial omics.
3 patents in this cluster (CN)Single-Cell & Sub-Tissue Resolution Spatial Metabolomics
A third cluster focuses on pushing spatial resolution to the single-cell level, reviewed in the context of plant biology where tissue-specific metabolite compartmentalization is of fundamental interest for crop improvement and natural product discovery. The review identifies IMS and microfluidics-based sampling as the primary enabling technologies, while flagging sensitivity and throughput as the principal bottlenecks that have not yet been resolved. This represents a clear R&D opportunity for instrument developers. See PatSnap Life Sciences solutions for biotech IP analytics.
Sensitivity: principal unresolved bottleneckComputational Metabolite Feature Inference & Deep Learning
A patent from Sun Yat-sen University (2023, CN active) describes a metabolic feature spectrum inference system that leverages LC-MS data and database matching at scale, addressing the annotation gap in untargeted metabolomics. In spatial metabolomics, only a fraction of detected ions are confidently annotated; deep learning–based inference applied to IMS data would represent a significant advancement in annotation completeness. The Zhejiang University patent (2025, pending) further describes a deep learning architecture computing cosine similarity scores in a joint embedding space to integrate spatial transcriptomics and spatial metabolomics at the individual spatial point level.
Sun Yat-sen Univ. 2023 · Zhejiang Univ. 2025From Oncology to Plant Biology: Where Spatial Metabolomics Is Being Applied
The retrieved records span four distinct application domains, with oncology representing the most mature deployment and plant single-cell metabolomics the most technically challenging frontier.
China Holds All Formal Patent Positions; Western Institutions Lead Open-Source Infrastructure
All spatial metabolomics patent filings in the retrieved dataset are concentrated in the CN jurisdiction. European and US institutions — including EMBL — are communicating innovations primarily through literature and open-source software.
| Assignee | Patent Count | Jurisdiction | Status | Focus Area |
|---|---|---|---|---|
| Shanghai Luming Biotech | 2 | CN | Active | Spatial transcriptomics–metabolomics co-registration pipeline |
| Zhejiang University | 1 | CN | Pending | Deep learning–based spatial multi-omics integration |
| Sun Yat-sen University | 1 | CN | Active | Metabolic feature spectrum inference via deep learning |
| EMBL / Multi-institutional | 0 (literature) | EU/US | Open-source | METASPACE, METASPACE-ML, SpatialData community platforms |
Five Frontier Directions from the 2023–2025 Filing and Publication Cohort
The most recent records in this dataset point to a convergence of machine learning, deep learning, and standardization as the defining forces shaping spatial metabolomics through 2026 and beyond.
Machine Learning–Driven IMS Annotation
METASPACE-ML (2023) demonstrates that replacing rule-based FDR scoring with machine learning trained on 1,710 heterogeneous datasets from 47 labs significantly improves precision, throughput, and recovery of low-intensity metabolites. This signals a shift from heuristic to data-driven annotation as the primary paradigm. Data access and curation are as strategically important as algorithm design.
Point-to-Point Spatial Transcriptomics–Metabolomics Co-Registration
Shanghai Luming Biotech patents (2023, 2025) establish a production-level computational pipeline for aligning IMS pixel grids to spatial transcriptomics spot arrays using fiducial landmarks derived from HE-stained tissue images. This addresses the practical workflow bottleneck for combined spatial multi-omics experiments, where the two technologies use fundamentally different coordinate systems and spatial scales.
Universal Spatial Omics Data Frameworks
SpatialData (2023) establishes a file format and coordinate system standard for spatial omics that explicitly supports IMS data alongside spatial transcriptomics platforms including Xenium and Visium. Standardization at the data layer is a prerequisite for multi-modal analysis at scale. Technology products built on or compatible with these standards will have a significant advantage in academic and translational market adoption.
IP White Space, Data Moats, and Standardization Dynamics
In this dataset, all formal patent filings specific to spatial metabolomics integration and annotation are from Chinese institutions. European and US innovators — including EMBL, the developer of METASPACE — are primarily using open-source publication strategies. R&D teams and IP strategists at Western instrument vendors and biotech companies should evaluate whether proprietary computational methods in this space warrant formal IP protection. For IP analytics tools, see PatSnap Analytics.
Multi-modal spatial omics integration is the highest-value near-term problem. Two of the four spatial metabolomics patents in this dataset specifically address spatial transcriptomics–spatial metabolomics co-registration. The technical challenge of aligning heterogeneous coordinate systems and resolution scales is a bottleneck for the entire field, and solutions — whether algorithmic or hardware-based — will be foundational infrastructure. The World Health Organization and translational research bodies increasingly recognize spatial omics as a priority tool for disease biology.
METASPACE-ML’s advantage derives directly from its access to 1,710 curated datasets from 47 labs. Organizations seeking to build competitive IMS annotation tools must either develop proprietary training data at comparable scale or build on the METASPACE knowledge base. The emergence of SpatialData as a universal spatial omics framework suggests the field is converging around open standards. See PatSnap customer case studies for examples of IP strategy in emerging biotech fields. The European Patent Office provides additional context on patent filing strategies in computational biology.
- IP white space exists in Western jurisdictions for spatial metabolomics computational tools — all formal patents in this dataset are CN
- Multi-modal spatial omics integration is the highest-value near-term problem; 2 of 4 patents address this directly
- ML model quality depends on annotated IMS dataset scale — METASPACE-ML trained on 1,710 datasets from 47 labs
- Single-cell spatial metabolomics remains technically immature; sensitivity and throughput are unresolved bottlenecks
- Standardization infrastructure (SpatialData, METASPACE) will determine market consolidation in spatial omics
Spatial Metabolomics — key questions answered
Spatial metabolomics is an emerging analytical discipline that maps the distribution of metabolites, lipids, and small molecules directly within tissue sections, preserving the spatial context lost in conventional bulk metabolomics.
IMS typically achieves spatial resolution ranging from 10 µm to 100 µm per pixel, depending on instrument configuration.
As of its 2019 publication, METASPACE already hosted over 3,000 datasets spanning human cancer cohorts, whole-body animal sections, and organ-level tissue maps. METASPACE-ML (2023) was trained on 1,710 datasets from 47 laboratories.
In the retrieved dataset, all formal patent filings specific to spatial metabolomics are from Chinese institutions: Shanghai Luming Biotech (2 active CN patents), Zhejiang University (1 pending CN patent), and Sun Yat-sen University (1 active CN patent).
The core challenge is that spatial transcriptomics chips use 55 µm diameter spots on a 6.5 mm × 6.5 mm array, while IMS operates on pixel grids at 100 µm × 100 µm resolution across areas up to 10 cm × 10 cm. Aligning these heterogeneous coordinate systems and resolution scales is the principal bottleneck.
METASPACE-ML (2023) replaces rule-based FDR scoring with a machine learning model trained on 1,710 heterogeneous datasets from 47 laboratories, achieving higher precision and better recovery of low-intensity, biologically relevant metabolites.
PatSnap Eureka searches patents and research literature to answer instantly.